SEC Form 4Coverage since Jun 5, 2026
$MGX insider trading
Over the last 12 months, Metagenomi Therapeutics insiders reported no purchases and 3 sales totaling $9K across SEC Form 4 filings.
- Bought · 12m
- — 0 events
- Sold · 12m
- $9K 3 events
- Events · 12m
- 3 Form 4 filings, grouped
- Insiders · 12m
- 3 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $MGX · 12Mvia TradingView
Top insiders · 12m
Wein MatthewSee Remarks1× · $725
Wapnick PamelaChief Financial Officer1× · $4K
Irish JianSee Remarks1× · $5K
All insider trades
3 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 5, 2026 | Wapnick PamelaChief Financial Officer · O | ▼ Sale | 2,884 | $1.3 | $4K | -1.4% | — |
| Jun 5, 2026 | Irish JianSee Remarks · O·D | ▼ Sale | 3,737 | $1.3 | $5K | -1% | — |
| Jun 5, 2026 | Wein MatthewSee Remarks · O | ▼ Sale | 558 | $1.3 | $725 | -0.4% | — |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $MGX feed.